Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk

Article excerpt

Women taking GLP-1 drugs like Ozempic and Wegovy showed about 30% lower breast cancer risk in a large study, suggesting the weight-loss medications may offer unexpected cancer protection. Researchers emphasize the findings are preliminary, association isn't causation, but promising enough to warrant clinical trials designed specifically to test whether these drugs could prevent breast cancer. The discovery adds another potential benefit to a class of medications already transforming obesity treatment, though experts caution that more rigorous evidence is needed before doctors could recommend them for cancer prevention.